key: cord-0064315-gfiilc9o
authors: Lara-Espinosa, Jacqueline V.; Arce-Aceves, María Fernanda; Mata-Espinosa, Dulce; Barrios-Payán, Jorge; Marquina-Castillo, Brenda; Hernández-Pando, Rogelio
title: The Therapeutic Effect of Intranasal Administration of Dexamethasone in Neuroinflammation Induced by Experimental Pulmonary Tuberculosis
date: 2021-06-01
journal: Int J Mol Sci
DOI: 10.3390/ijms22115997
sha: 0a88edc0de38844687d710deb6f726f76714b76f
doc_id: 64315
cord_uid: gfiilc9o

Tuberculosis (TB) is an important infectious disease and a public health problem. The organs most frequently affected by TB are the lungs; despite this, it has been reported that TB patients suffer from depression and anxiety, which have been attributed to social factors. In previous experimental work, we observed that the extensive pulmonary inflammation characteristic of TB with high cytokine production induces neuroinflammation, neuronal death and behavioral abnormalities in the absence of brain infection. The objective of the present work was to reduce this neuroinflammation and avoid the psycho-affective disorders showed during pulmonary TB. Glucocorticoids (GCs) are the first-line treatment for neuroinflammation; however, their systemic administration generates various side effects, mostly aggravating pulmonary TB due to immunosuppression of cellular immunity. Intranasal administration is a route that allows drugs to be released directly in the brain through the olfactory nerve, reducing their doses and side effects. In the present work, dexamethasone’s (DEX) intranasal administration was evaluated in TB BALB /c mice comparing three different doses (0.05, 0.25 and 2.5 mg/kg BW) on lung disease evolution, neuroinflammation and behavioral alterations. Low doses of dexamethasone significantly decreased neuroinflammation, improving behavioral status without aggravating lung disease.

Inflammation is a response of vascular living tissues to injury [1] . The inflammatory response is the coordinated activation of signaling pathways in resident tissue cells and inflammatory cells recruited from the blood that control inflammatory mediators' levels. [2] . There are two types of inflammatory responses, acute and chronic. Acute inflammation refers to the instantaneous or early response to an injurious agent and is a defensive response that paves the way for repairing the damaged site and consists on the leukocytic infiltration of predominantly polymorphonuclear cells (neutrophils) [1] . Chronic inflammation results from a persistent injurious agent and is characterized by a leukocyte infiltrate constituted by mononuclear cells (macrophages, lymphocytes, plasma cells) [1] that can lead to tissue damage [3] .

For a long time, the central nervous system (CNS) was considered as an immuneprivileged tissue, isolated from peripheral immune cells unable to cross the blood-brain barrier (BBB) under normal conditions [4] . However, recent data indicate that the CNS is immune-competent and actively cooperative with the peripheral immune system [4] .

Immune activation in the CNS always involves microglia and astrocytes, which contribute to the homeostatic regulation of the brain tissue [5] . Microglia and astrocytes . p = 0.2191, Logrank test for trend. Data are presented as mean +/− SEM. The H/DEX dose significantly increased the bacterial load in the lung and brain from day 60 post-infection and decrease survival rate, while the L/DEX and M/DEX doses did not increase the number of bacteria in these organs. Thus, bacterial load in the lung and brain from day 60 post-infection and decrease survival rate, while the L/DEX and M/DEX doses are safe to administer in animals infected with Mtb, as they do not aggravate lung disease.

In previous work we observed that pulmonary infection with M. tb induced sickness behavior, manifested by a significant decrease in body weight and locomotor activity in infected animals [33] . Sickness behavior is a response related to the inflammatory process. Thus, we determined the effect of IN L/DEX and M/DEX doses administration during early Mtb infection on sickness behavior. The results showed that the treatment with L/DEX and M/DEX doses decrease the sickness behavior of TB mice ( Figure 2 ). There was a slight improvement in body weight, mostly at 90-and 120-days post-infection and locomotor activity (LMA) was also significantly improved after one week of treatment. Another crucial behavioral change observed in both animals infected with Mtb and TB patients is anxiety. Indeed, we found that lung inflammation generated anxiety-like behaviour in our model of pulmonary TB [33] . Thus, we evaluated the IN L/DEX and M/DEX treatment's effect on infected animals that showed anxiety-like behavior using the elevated I-maze [34] , which is a modification of the elevated plus-maze model of anxiety in mice. We observed that the treatment with L/DEX and M/DEX doses increased the time spent by mice on the open arm (TO) and unprotected head dips (uHDIPS) at 60 and 120 post-infections in TB mice, and also reduced the protected head dips (pHDIPS) and Another crucial behavioral change observed in both animals infected with Mtb and TB patients is anxiety. Indeed, we found that lung inflammation generated anxiety-like behaviour in our model of pulmonary TB [33] . Thus, we evaluated the IN L/DEX and M/DEX treatment's effect on infected animals that showed anxiety-like behavior using the elevated I-maze [34] , which is a modification of the elevated plus-maze model of anxiety in mice. We observed that the treatment with L/DEX and M/DEX doses increased the time spent by mice on the open arm (TO) and unprotected head dips (uHDIPS) at 60 and 120 post-infections in TB mice, and also reduced the protected head dips (pHDIPS) and stretched attend postures (SAP) (Figure 3) . Thus, the treatment with IN DEX showed an anxiolytic-like activity on TB mice. Data are presented as mean +/− SEM. DEX produced a significant increase in %TO, an increase in uHDIPS, a decrease in pHDIPS, and a decrease in SAP compared to the saline-treated mice at days 60 and 120 post-infection. All these data suggest that DEX has an anxiolytic-like activity on TB mice.

We have previously demonstrated that pulmonary infection with M. tb induces depression-like behavior and neurological damage in a TB murine model [33] . We evaluated the IN DEX administration on these changes. The results showed that IN DEX decreased the depression-like behavior significantly in the Tail suspension test since day 21 postinfection ( Figure 4 ). Similar results were seen in the evaluation of neurological damage, which significantly decreased since day 28 post-infection ( Figure 4 ). It would seem that IN DEX had an anti-depressive effect and produced a beneficial effect on the neurological outcome of the infected animals. . Data are presented as mean +/− SEM. DEX produced a significant increase in %TO, an increase in uHDIPS, a decrease in pHDIPS, and a decrease in SAP compared to the saline-treated mice at days 60 and 120 post-infection. All these data suggest that DEX has an anxiolytic-like activity on TB mice.

We have previously demonstrated that pulmonary infection with M. tb induces depression-like behavior and neurological damage in a TB murine model [33] . We evaluated the IN DEX administration on these changes. The results showed that IN DEX decreased the depression-like behavior significantly in the Tail suspension test since day Previously, we observed that pulmonary infection with M. tb induces damage in short-term memory from day 14 post-infection and in long-term memory from day 1 postinfection [33] . The IN DEX treatment improved the short-and long-term memory in the object recognition test of TB mice ( Figure 5 ). Previously, we observed that pulmonary infection with M. tb induces damage in short-term memory from day 14 post-infection and in long-term memory from day 1 postinfection [33] . The IN DEX treatment improved the short-and long-term memory in the object recognition test of TB mice ( Figure 5 ). 

Pro-inflammatory cytokines in the brain are produced during pulmonary TB without bacterial infection in the SNC [33] . We determined by RT-PCR the effect of IN DEX in the brain expression of TNFa, IFNg and IL-12 levels in the hippocampus, hypothalamus, cerebellum and frontal cortex. Our results showed that 0.05 and 0.25 mg/ Kg BW of IN DEX 

Pro-inflammatory cytokines in the brain are produced during pulmonary TB without bacterial infection in the SNC [33] . We determined by RT-PCR the effect of IN DEX in the brain expression of TNFa, IFNg and IL-12 levels in the hippocampus, hypothalamus, cerebellum and frontal cortex. Our results showed that 0.05 and 0.25 mg/Kg BW of IN DEX administration significantly decreased the expression of these cytokines in the hippocampus ( Figure 6 ) and hypothalamus ( Figure 7 ) of mice infected with M. tb, compared to the group that received saline solution. In the cerebellum, we observed that although there was a decrease in these pro-inflammatory cytokines, the reduction was lesser than in the hippocampus and hypothalamus ( Figure 8 ). In the frontal cortex, both doses of DEX significantly decreased the expression of these pro-inflammatory cytokines, although a more significant effect was observed with the dose of 0.25 mg/Kg BW ( Figure 9 ).

Altogether, these results suggest that intranasal administration of L/DEX and M/DEX doses reduces neuroinflammation in the murine model of experimental pulmonary TB. Taken together, our results demonstrate that intranasal administration of L/DEX and M/DEX in a mouse model of pulmonary TB does not aggravate lung disease. Furthermore, it effectively reduces the gene expression of TNFα, IFNγ and IL-12 in the hippocampus, hypothalamus, cerebellum and frontal cortex of infected animals. The sickness behavior, anxiety and depression-like behavior decreased, and there was an improvement in shortand long-term memory. Taken together, our results demonstrate that intranasal administration of L/DEX and M/DEX in a mouse model of pulmonary TB does not aggravate lung disease. Furthermore, it effectively reduces the gene expression of TNFα, IFNγ and IL-12 in the hippocampus, hypothalamus, cerebellum and frontal cortex of infected animals. The sickness behavior, anxiety and depression-like behavior decreased, and there was an improvement in shortand long-term memory.

TB is a significant cause of mortality in developing countries. The incidence of this condition is still increasing [19] . A generalized pro-inflammatory state is an early characteristic of TB and contributes to severe pathology. Furthermore, TB patients suffer common mental disorders such as depression and anxiety [22] . Previously, we have shown that in the absence of cultivable bacteria in the brain, M. tb induces neuroinflammation, neuronal damage, and behavioral abnormalities during pulmonary infection, manifested by high production of different cytokines, mainly TNFα, IFNγ, and IL12 [33] . This condition produced neuronal death, so it requires therapeutic approaches that modulate this pro-inflammatory response to avoid neuronal injury and behavioral abnormalities. From 

TB is a significant cause of mortality in developing countries. The incidence of this condition is still increasing [19] . A generalized pro-inflammatory state is an early characteristic of TB and contributes to severe pathology. Furthermore, TB patients suffer common mental disorders such as depression and anxiety [22] . Previously, we have shown that in the absence of cultivable bacteria in the brain, M. tb induces neuroinflammation, neuronal damage, and behavioral abnormalities during pulmonary infection, manifested by high production of different cytokines, mainly TNFα, IFNγ, and IL12 [33] . This condition produced neuronal death, so it requires therapeutic approaches that modulate this pro-inflammatory response to avoid neuronal injury and behavioral abnormalities. From the therapeutic perspective, IN drug administration is advantageous for treating CNS disorders, as demonstrated in multiple studies [35] . IN GCs delivery has recently been proven to control experimental neuroinflammation induced by systemic lipopolysaccharide (LPS) injection in an experimental model of sepsis [17] . In that report, IN delivery of DEX effectively reduced the percentage of the Glial fibrillary acidic protein (GFAP) brain cells that were increased by LPS, reduced the presence of neutrophils in the brain and decreased Interleukin-6 (IL) expression [17] . Interestingly, the protective anti-inflammatory effects were less pronounced when DEX was delivered at the same dose through the intra-venous (IV) route. Similar results have been observed in a 60-min middle cerebral artery occlusion stroke model. IN DEX reduced strikingly the ischemic brain tissue damage, reduced blood-brain barrier permeability, decreased mortality and improved the Neurological deficit (7-point neuroscore scale) and weight of animals [14] . Another study showed that intranasal administration of methylprednisolone to mice with experimental autoimmune encephalomyelitis (EAE) suppressed the neuroinflammatory response and reduced immune cell infiltration and demyelination, in a similarly way to intravenous administration [36] . Thus, these results suggest that IN GCs administration might offer a more effective and practical alternative than systemic administration to treat neuroinflammation in diverse diseases which coincides with our results.

GCs are steroid hormones produced by the adrenal gland and regulated by the hypothalamus-pituitary-adrenal axis (HPA) and are the most used anti-inflammatory and immunomodulatory agents [10] . Their therapeutic value is enormous in a wide range of autoimmune/inflammatory diseases, and GCs have been widely used for treating autoimmune disorders, allergies, allograft rejection, neuroinflammation, and neoplastic diseases [10] . In this context, DEX, a potent anti-inflammatory synthetic GC, has been used to reduce inflammation in different neuroinflammatory conditions [14, 17, 37] . In the present study, we showed that treatment with L/DEX (0.05 mg/kg BW) and M/DEX (0.25 mg/kg BW) through the IN route in the murine pulmonary TB model significantly decreased neuroinflammation, improving behavioral status without aggravating lung disease.

We show that treatment since early infection (two weeks post-infection) with L/DEX and M/DEX by IN route improves survival in TB mice, while H/DEX (2.5 mg/kg BW) showed no survival benefit and increased bacilli load in the lung and dissemination with bacterial growth in the brain of mice. Interestingly L/DEX treatment was associated with a significantly lower lung bacilli load on day 120 post-infection. Similar results have been found during early sepsis in mice, where L/DEX treatment significantly improved survival compared with control mice, while treatment with higher DEX concentrations did not. Besides, L/DEX significantly reduced bacteremia [38] . In recent years, it has been observed that GCs reinforce the innate immune system and repress the adaptive immune system to help resolve inflammation and restore homeostasis [39] . GCs induce the expression of Toll-Like Receptor 2 (TLR2), NOD-like receptors family pyrin domain containing 3 (NLRP3) inflammasome and the purinergic P2Y2 receptor (P2Y2R), all of these receptors participate in innate immunity [40] [41] [42] . The type of exposure to glucocorticoids and the basal state of the immune system are essential factors influencing the effects of GCs [10] . The innate immune system is fundamental for the initial immune response upon infection [43] , thus it could be possible that the decrease in lung bacilli lung in the murine model of TB is related to reinforcement of innate immunity mediated by L/DEX.

As we had observed that pulmonary infection by M. tb induced behavioral abnormalities [33] , we investigated the IN DEX administration effect on diverse behavioral abnormalities. Our results showed that the treatment with IN L/DEX and M/DEX decreased sickness behavior, induced an anxiolytic effect, reduced the depression-like behavior, produced a beneficial effect on the neurological outcome and improved the short and long term memory of the pulmonary infected TB mice. Active TB starts as a pulmonary exudative inflammatory process. Th1 lymphocytes mediate the protective adaptive immune response against TB with high production of IFN-γ and CD8+ T cytotoxic cells in animals and humans (Table 1 ) [44] . Pro-inflammatory cytokines such as IFNγ and TNFα might induce the development of depressive disorder by affecting neuronal excitability, synaptic transmission, synaptic plasticity, and neuronal survival. These abnormal activities are produced by brain inflammation, which induces depression by diverse pathophysiological processes, such as disturbing monoaminergic neurotransmission, induce oxidative injury, and hippocampal neuronal damage. Indeed, DEX has been used to reduce inflammation in diverse neuroinflammatory conditions [14, 17] . Different studies demonstrated that the anti-inflammatory effects of glucocorticoids such as DEX were attributable to the reduced expression of IL1β, IL2, TGFβ, and TNFα [42] . Diverse evidence based on experimental studies demonstrated that GCs participate in the survival and death of neurons in both neurodegenerative and neuroprotective processes [43] . The binomial effect of GCs in the brain depends on the levels of GCs [43] . This coincides with our results, demonstrating that L/DEX and M/DEX effects on behavioral abnormalities are associated with a marked decrease in the inflammatory response. We found that mRNA expression levels of the inflammatory cytokines TNFα, IL12 and IFNγ were significantly downregulated in the treated group compared to the control non-treated TB group. It is known that low doses of GCs are more beneficial, preserving the physiological metabolism of the neurons and the HPA axis [43] . Interestingly, relatively low dose DEX administration (1 mg/kg, intraperitoneal injection) has been shown to attenuate inflammation and decrease ED1-positive cells and three markers of inflammatory activation of microglia/macrophage in murine models of traumatic brain injury (TBI) [12, 45] . Similar results were found with hydrogel-mediated local delivery of dexamethasone that reduced neuroinflammation and improved functional motor recovery [46] . Another study reported that dexamethasone alone (0.025 mg/kg) and the co-administration of melatonin and dexamethasone 24 h after TBI improved locomotor function and brain injury [47] . Thereby, DEX has an efficient protective effect on neuroinflammation.

Summarizing the results obtained in this experimental study demonstrated the effectiveness of low dose GC IN administration as a new therapy to control neuroinflammation in chronic infectious diseases, such as pulmonary TB. IN drug delivery is desirable because it is noninvasive, and can therapeutically target the brain, reducing systemic side effects [18, 48] . It is important to highlight that IN L/DEX and M/DEX did not aggravate the lung disease, thereby IN DEX could be used as a co-adjuvant treatment in conventional chemotherapy against TB. [49] . The systemic administration of DEX in TB would decrease the pro-inflammatory response, which is essential for protecting against the bacilli in this infectious disease. IN DEX allows the direct treatment to the CNS. Therefore, it does not aggravate lung disease.

The Middlebrook 7H9 and 7H10 media and the OADC (oleic acid, albumin, dextrose and catalase) were obtained from Becton-Dickinson (Detroit, MI, USA). The Rneasy ® Mini Kit for RNA extraction, the Omniscript ® Reverse Transcription Kit for obtaining complementary DNA and the QuantiTectTM SYBR ® for RT-PCR were obtained from Qiagen (Germantown, MD, USA). The primers of the analysed cytokines were obtained from InvitrogenTM Thermo Fisher Scientific (Waltham, MA, USA). The DEX was obtained from Sigma Aldrich (Zwijndrecht, The Netherlands).

A total of 384 adult male BALB/c mice of eight weeks old were obtained from the animal house facility of the National Institute of Medical Science and Nutrition Salvador Zubiran (INCMNSZ), Mexico. Mice were group-housed (n = 5/cage) and randomly divided into two groups: control (CT, n = 144) and infected (H37Rv, n = 240). All the animals were kept in an accredited animal holding facility maintained at a controlled temperature (23 ± 1 • C) and humidity (50 ± 20%) under a 12:12 h light-dark cycle (lights on at 07:00 h). Food and water were provided ad libitum. All the animal experiments were done according to the guidelines of the ARRIVE and Mexican Constitution law NOM 062-Z00-1999 and approval by the Ethical Committee for Experimentation in Animals of the INCMNSZ in Mexico, protocol number: PAT-1865-16/19-1.

The murine model of progressive pulmonary TB was described previously [50, 51] . Briefly, the reference M. tb strain H37Rv was cultured in 7H9 medium with OADC enrichment. Mid-log-phase cultures were used for all experiments. M. tb were counted and stored at −80 • C until use. Bacterial aliquots were thawed and pulse-sonicated to remove clumps. After mice infection, the bacterial inoculum's remnant was plated to confirm the CFU's number and viability administered to the animals. Male BALB/c mice, 8 weeks of age, were anaesthetized in a gas chamber using 0.1 mL of sevoflurane per mouse. A blunt stainless-steel cannula with a small ball in its terminal end was inserted through the mouth and directed to the trachea. The cannula's proper intratracheal placement was verified by palpation of the small ball from the cannula rubbing the tracheal rings. Mice were infected through intratracheal instillation with 2.5 × 10 5 live bacilli.

Mice were maintained in a vertical position until spontaneous recovery. A total of 244 infected mice were maintained in groups of five in cages fitted with micro-isolators in a P-3 biosecurity level facility.

We analyzed the effects of IN DEX administration on the CNS inflammation of pulmonary TB mice. In the first part of the work, we evaluated the effect of the treatment on lung disease ( Figure 10 ). Following infection, mice were treated since day 14 postinfection and then euthanized by exsanguination under anesthesia at days 21, 28, 60, and 120 post-infection; lungs and brain were collected immediately to determine bacillary loads by CFU counts, and the survival was monitored during the complete experiment. In the second part of the work, we evaluated IN DEX administration's effect on sickness behavior, behavioral abnormalities, and immune response in different brain structures ( Figure 11 ). The selected areas of the brain (hypothalamus, hippocampus, cerebellum, frontal cortex) were immediately dissected by cutting with a razor blade, according to The Mouse Brain in Stereotaxic Coordinates [52] . The hippocampus was obtained underneath the frontal cortex, the cerebellum was identified as between the brainstem and the lateral recess of the 4th ventricle, the hypothalamus was obtained as the area lateral and medial to the fornix and the frontal cortex was obtained as the anterior part of the frontal lobes of the brain. Immediately after the dissection, the sample was frozen by immersion in liquid nitrogen and used to quantify cytokines gene expression by RT-PCR. Different behavioral tests were performed during pulmonary TB. These tests included the study of sickness behavior (LMA. Food intake and weight loss), anxiety-like behavior, NSS, short and long-term memory and depression-like behavior. Animals were monitored daily and were humanely euthanized under pentobarbital anesthesia if respiratory insufficiency, accentuated cachexia, or total immobilization was noted. Two independent experiments were performed.

After 14 days of infection, groups of three mice in two independent experiments were treated with 0.05 mg/kg, 0.25 mg/kg, or 2.5 mg/kg of dexamethasone administered by intranasal route (20 µL) three days per week (Monday, Wednesday, and Friday). Control mice received 20 µL of saline solution.

manely euthanized under pentobarbital anesthesia if respiratory insufficiency, accentuated cachexia, or total immobilization was noted. Two independent experiments were performed. manely euthanized under pentobarbital anesthesia if respiratory insufficiency, accentuated cachexia, or total immobilization was noted. Two independent experiments were performed. 

Right lungs and the brains' right hemisphere from six mice at each time point of two independent experiments were used for bacterial colony counting. Lungs and brains were homogenized with a FastPrep homogenizer (MP Biomedicals) in sterile tubes containing 1 mL of isotonic saline solution. Four homogenate dilutions were spread onto duplicate plates containing Bacto Middlebrook 7H10 agar, enriched with OADC. Incubation time and CFU counting were at 21 days of plating [51] .

Hippocampus, hypothalamus, cerebellums, and frontal cortex from six CT and infected animals at each time point were used to isolate mRNA using the Rneasy Mini Kit, according to the manufacturer's recommendations. The quality and quantity of RNA were evaluated through spectrophotometry (260/280) and on agarose gels. Reverse transcription of the mRNA was performed using 100µg RNA, oligo dT, and the Omniscript kit. Real-time PCR was performed using the 7500 RT-PCR system (Applied Biosystems, Foster City, CA, USA) and Quantitec SYBR Green Mastermix kit (Qiagen). Negative controls were included in each PCR run. Specific primers for genes encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene and for TNF-α, IFN-γ and Interleukin (IL) 12 were designed using the program Primer Express (Applied Biosystems, USA). Cycling conditions used were: initial denaturation at 95 • C for 15 min, followed by 40 cycles at 95 • C for 20 s, 60 • C for 20 s, and 72 • C for 34 s. Each sample was tested in duplicate. The fold change of gene expression was calculated by the 2 −( Ct) method [53] .

The behavior test methodology in the murine model of progressive pulmonary TB was described previously [33] . Briefly, animals were habituated to the test environment 24 h before it was made. Groups of mice were tested only once at the mentioned time points post-treatment to avoid potential habituation. All behavioral trials were performed during the first 4 h of the dark phase of the light cycle. The behaviors were analyzed and documented by a blind observer from these recordings.

To estimate sickness behavior, we evaluated LMA, food intake and weight loss. The effect of M. tb lung infection on LMA was evaluated in an open field by quantifying the mice's moving time for 10 min. Data are represented as the per cent of moving during the 10 min. Twice a week the amount of food given to mice was weighed to determine food intake, and the total ingesting of food by mice was calculated. Data are expressed as g/mouse/day. The weight loss of the animals infected with M. tb was estimated from day one post-infection until day 120. Each week the animals were weighted, and their loss weight recorded. Data are represented as g of body weight.

We evaluated depression-like behavior with the tail suspension test [54] . For this test, animals were suspended from the tail 6 min in a tripod 30 cm height, and their activity was recorded, focusing on the time that mice spent in behavioral despair. The time that the animal presented behavioral despair in those 6 min was recorded.

The anxiety-like behavior was evaluated in the elevated I-maze, which modified the elevated plus-maze model of anxiety in mice [34] . The design of I-maze comprises a straight wooden passage, resembling the English letter "I," divided equally into three areas; two enclosed areas (close arms) at both ends of the "maze" and an open area in the center of two enclosed areas. Animals were observed for 5 min duration, and %TO, Phdips, uHDIPS, and SAP were quantified.

Motor function and reflexes of the infected mice were evaluated using a neurological severity score (NSS) [55] . They were valued regarding absent (0) or present (1), except for the hypomobility, motor impairment and balance that were rated as weak (1), moderate (2) or strong (3) . The maximum score rates 31 (indicating neurological damage). Usual rate, from 3 to 6 (normal).

Memory and learning after pulmonary infection with M. tb were assessed with the Object Recognition Test [56] . With this test, we evaluated short-term and long-term memory. In the first habituation phase, we placed the animal in the open field without any object for 10 min to become familiar with the environment. At 24 h, two identical objects (objects A) were placed in different positions, and the animal was left inside the box for 3 min. In the next phase, 30 min later, short-term memory was measured; for this, we positioned an object A (familiar object) and placed a new object in the other position (object B), the interactions with both objects (the animal sniffs or touches the object with the front legs) were counted during 3 min. After 24 h, the long-term memory was measured, for which object B was changed to a novel object (C), and the same procedure was followed. The results are presented as the discrimination ratio, which is the difference in interactions expressed as a proportion of the two objects' total interactions in both tasks.

Data are expressed as the mean ± standard error of the mean (SEM) of two independent experiments. All data collection was randomized and tested with the Shapiro-Wilk normality test. The survival curves were analyzed with Logrank test for trend. Statistical significance of the bacilli load, body weight, locomotor activity and the behavioral tests was assessed using two-way ANOVA, followed by Tukey's multiple comparisons test or Dunnett's multiple comparisons test (comparison of each group against the saline control) as specified in the related text. The mixed-effects model analyzed cytokine expression by RT-PCR. Statistical significance was set at p < 0.05 for all experiments. Statistical analyses were performed in GraphPad Prism (v 9.1.1.225) (GraphPad, San Diego, CA, USA) [57] .

The intranasal administration of dexamethasone at low doses reduced TNFα, IFNγ, and IL12 expression in the hippocampus, cerebellum, hypothalamus, and frontal cortex of animals infected with M. tb. The treatment improved the behavioral changes present in animals with TB, decreased sickness behavior, depression, anxiety, neurological damage, and memory damage ( Figure 12 ). It is important to note that it does not aggravate the lung disease so it could be used as adjuvant therapy to conventional anti-tuberculosis treatment. These are ongoing experiments in our laboratory. of animals infected with M. tb. The treatment improved the behavioral changes present in animals with TB, decreased sickness behavior, depression, anxiety, neurological damage, and memory damage ( Figure 12 ). It is important to note that it does not aggravate the lung disease so it could be used as adjuvant therapy to conventional anti-tuberculosis treatment. These are ongoing experiments in our laboratory. 

The data presented in this study are available on request from the corresponding author.

The authors of this manuscript declare that there are no actual or potential conflict of interest. The authors affirm that there are no financial, personal or other relationships with other people or organizations that have inappropriately influenced or biased their research.

Inflammatory responses and inflammationassociated diseases in organs

The nuclear factor NF-kappaB pathway in inflammation

Sepsis: Developing new alternatives to reduce neuroinflammation and attenuate brain injury

CNS immune privilege: Hiding in plain sight

Inflammatory Response in the CNS: Friend or Foe?

Neuroinflammation pathways: A general review

Infectious immunity in the central nervous system and brain function

Neuroinflammation Induces Neurodegeneration

Strategies toward rheumatoid arthritis therapy; the old and the new

Mechanisms of the anti-inflammatory effects of glucocorticoids: Genomic and nongenomic interference with MAPK signaling pathways

One hormone, two actions: Anti-And pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation

Dexamethasone attenuates early expression of three molecules associated with microglia/macrophages activation following rat traumatic brain injury

Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis

Intranasal Dexamethasone Reduces Mortality and Brain Damage in a Mouse Experimental Is-chemic Stroke Model

Advances with glucocorticoids in the treatment of asthma: State of the art

Systemic side effects of inhaled corticosteroids in patients with asthma

Intranasal delivery of dexamethasone efficiently controls LPS-induced murine neuroinflammation

The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview

The Future of Vaccines for Tuberculosis

Evidence for the Effect of Vaccination on Host-Pathogen Interactions in a Murine Model of Pulmonary Tuberculosis by Mycobacterium tuberculosis

Psychiatric Problems in Pulmonary Tuberculosis: Depression and Anxiety

Association of pulmonary tuberculosis and ethambutol with incident depressive disorder: A nationwide, population-based cohort study

Depression and its Associated Factors with Multidrug-Resistant Tuberculosis at Baseline

Psychiatric morbidity in pulmonary tuberculosis-A clinical study

Depression: A neglected comorbidity in patients with tuberculosis

Passage of Cytokines across the Blood-Brain Barrier

Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin 1β-induced ACTH release

Cytokine-to-brain communication: A review & analysis of alternative mechanisms

A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder

Sickness Behavior, and Depression

From early adversities to immune activation in psychiatric disorders: The role of the sympathetic nervous system

Experimental pulmonary tuberculosis in the absence of detectable brain infection induces neuroinflammation and behavioural abnormalities in male balb/c mice

Behavioral and biochemical characterisation of elevated "I-maze" as animal model of anxiety. Beni-Suef Univ

Drug delivery systems, CNS protection, and the blood brain barrier

Intranasal methylprednisolone effectively reduces neuroinflammation in mice with experimental auto-immune encephalitis

Dexamethasone and betamethasone protect against lip-opolysaccharide-induced brain damage in neonatal rats

Mild versus strong anti-inflammatory therapy during early sepsis in mice: A matter of life and death

The five Rs of glucocorticoid action during inflammation: Ready, reinforce, repress, resolve, and restore

Glucocorticoids and the innate immune system: Crosstalk with the Toll-like receptor signaling network

Glucocorticoids sensitise the innate immune system through regulation of the NLRP3 inflammasome

Dexamethasone enhances ATP-induced inflammatory responses in en-dothelial cells

Concentration Dependent Actions of Glucocorticoids on Neuronal Viability and Sur-vival

Immune factors and immunoregulation in tuberculosis. Brazilian

Dexamethasone and colchicine reduce inflammation and delayed oedema following experimental brain contusion

Hydrogel-mediated local delivery of dexamethasone reduces neuroinflammation after traumatic brain injury

Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury

Safety of intranasal corticosteroids

Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): A Review. SN Compr

Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis

Specific bacterial genotypes of Mycobacterium tuberculosis cause extensive dissemination and brain infection in an experimental model

Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates

Analysing real-time PCR data by the comparative CT method

Animal models of neuropsychiatric disorders

Experimental closed head injury: Analysis of neurological outcome, blood-brain barrier dysfunction, in-tracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines

Spontaneous object recognition and object location memory in rats: The effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix

GraphPad Software; Version 9.1.1.225; Software for Biostatistics